四环医药的2024年:医美销售增65.4%,仿制药降21.4%

财中社
28 Mar

3月28日,四环医药(00460)发布截至2024年12月31日止年度的全年业绩公告。业绩显示,公司总收益约为19.01亿元,同比上升约2.2%。其中,来自医美业务的销售收益约为7.44亿元,同比大幅上升约65.4%,主要由于产品在市场上的高度认可及新产品销售的推动。相反,仿制药业务的销售收益约为10.99亿元,同比下降约21.4%,主要受到集采政策和部分产品被纳入重点监控目录的影响,导致整体...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10